US grant for Immunomedics' breast cancer agent:
This article was originally published in Clinica
Immunomedics has received a US grant to test an imaging peptide for diagnosing breast cancer. The company has developed a peptide labelled with the nuclear isotope technetium-99m that binds to a receptor which is increased in breast and several other cancers. The Phase I study is expected to demonstrate the peptide's ability to image human breast cancer.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.